Li Zongyang, Gu Zheng, Xiang Jingyu, Zhang Xiaoyan
Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Department of Dermatology, China-Japan Friendship Hospital, Beijing, China.
Front Med (Lausanne). 2025 May 2;12:1593003. doi: 10.3389/fmed.2025.1593003. eCollection 2025.
To explore the association between psoriasis and metabolic syndrome (MetS) and analyze the impact of disease activity on the risk of MetS occurrence.
This systematic review and meta-analysis used computer searches to search for relevant literature on psoriasis and MetS in databases including China National Knowledge Infrastructure (CNKI), PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase. The search period was from the establishment of the database to February 8, 2025. Inclusion in case-control, cohort studies and cross-sectional, with language restrictions in Chinese and English during retrieval. After independent screening of literature, extraction of data, and evaluation of risk bias for inclusion in the study by two evaluators, meta-analysis and subgroup analysis were conducted using Stata17.0 software.
A total of 12 studies were analyzed, encompassing 9,641 patients with psoriasis and 2,554 patients suffering from MetS alongside psoriasis. The incidence of metabolic syndrome in psoriasis patients was analyzed and the combined effect size was 26.49% [95% CI (25.61, 27.39%)]. Results from the meta-analysis indicated that, in comparison to the control group, psoriasis patients demonstrated a heightened risk of developing MetS [OR = 1.27, 95% CI (1.21-1.33), < 0.001]. Subgroup analysis revealed that patients with severe psoriasis (PASI≥10) had a significantly increased risk of developing metabolic syndrome [OR = 2.25 95% CI (1.27, 3.99), < 0.001], indicating that greater disease activity is associated with an elevated likelihood of MetS occurrence.
Psoriasis is positively correlated with MetS risk, and increased disease activity further increases the risk. It is necessary to strengthen screening for metabolic abnormalities and multidisciplinary management.
探讨银屑病与代谢综合征（MetS）之间的关联，并分析疾病活动度对MetS发生风险的影响。
本系统评价和荟萃分析通过计算机检索中国知网（CNKI）、PubMed、Web of Science、Cochrane对照试验中心注册库（CENTRAL）和Embase等数据库中关于银屑病与MetS的相关文献。检索时间为各数据库建库至2025年2月8日。纳入病例对照研究、队列研究和横断面研究，检索时限定语言为中文和英文。由两名评价员独立进行文献筛选、数据提取及纳入研究的风险偏倚评估后，使用Stata17.0软件进行荟萃分析和亚组分析。
共分析12项研究，包括9641例银屑病患者和2554例合并银屑病的MetS患者。分析银屑病患者代谢综合征的发病率，合并效应量为26.49%[95%可信区间（25.61，27.39%）]。荟萃分析结果表明，与对照组相比，银屑病患者发生MetS的风险更高[比值比（OR）=1.27，95%可信区间（1.21 - 1.33），P<0.001]。亚组分析显示，重度银屑病患者（银屑病面积和严重程度指数评分≥10）发生代谢综合征的风险显著增加[OR = 2.25，95%可信区间（1.27，3.99），P<0.001]，表明疾病活动度越高，发生MetS的可能性越大。
银屑病与MetS风险呈正相关，疾病活动度增加会进一步提高风险。有必要加强代谢异常筛查和多学科管理。
